Jul. 2 at 9:45 PM
$JSPR looks like market starting to wake up to the huge valuation gap between JSPR and
$CLDX. CLDX at
$1.4B market cap and JSPR only
$100M. If JSPR can demonstrate a better efficacy/safety profile than CLDX with this month's CSU key data, expect that gap to narrow considerably. Obv there are some nuances - CLDX having more cash, ahead in timeline, etc, but this is a similar setup to what happened with
$DRUG and
$LBPH. Assuming no dilution, a
$1.4B market cap would be
$93 for JSPR, 100% dilution would be
$46. Things can get crazy with 15M O/S
